{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.06","value":"73.2"},{"groupId":"OG001","spread":"21.31","value":"72.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Disease Symptoms: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.75","value":"73.5"},{"groupId":"OG001","spread":"23.09","value":"68.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"title":"Disease Symptoms: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.45","value":"81.0"},{"groupId":"OG001","spread":"13.30","value":"81.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Side Effects of Treatment: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.84","value":"74.4"},{"groupId":"OG001","spread":"14.47","value":"77.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"title":"Side Effects of Treatment: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.09","value":"81.5"},{"groupId":"OG001","spread":"23.90","value":"82.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Body Image: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.93","value":"75.0"},{"groupId":"OG001","spread":"23.71","value":"83.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"title":"Body Image: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.29","value":"58.8"},{"groupId":"OG001","spread":"24.03","value":"67.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Future Perspective: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.26","value":"57.9"},{"groupId":"OG001","spread":"19.21","value":"64.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"title":"Future Perspective: End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"The EORTC QLQ-MY20 has 20 items across 4 independent subscales, 2 symptoms scales (disease symptoms, side effects of treatment), and 2 functional subscales (body image, future perspective). Scores were averaged and transformed to 0-100 scale. Higher scores for the future perspective scale indicate better perspective of the future, for the body image scale indicate better body image and for the disease symptoms scale indicate higher level of symptomatology.","dispersionType":"Standard Deviation","groups":[{"description":"Pomalidomide 4 mg, capsules, orally, once daily on Days 1 to 21 of each 28-day cycle, plus dexamethasone 40 mg, (or 20 mg if participant is aged \\>=75 years), tablets, orally, once daily on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.","id":"OG000","title":"Pomalidomide 4 mg + Dexamethasone 40 mg"},{"description":"Ixazomib 4 mg as starting dose, capsules, orally, once daily on Days 1, 8, and 15 of each 28-day cycle, with escalation to 5.5 mg at the start of Cycle 2 for participants who tolerated the 4 mg dose in Cycle 1, plus dexamethasone 20 mg (or 10 mg if participant is aged \\>=75 years), tablets, orally, once daily on Days 1, 2, 8, 9, 15, 16, 22, and 23 of every 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.","id":"OG001","title":"Ixazomib 4 mg + Dexamethasone 20 mg"}],"paramType":"MEAN","populationDescription":"ITT PRO Population included participants with a measurement at study entry and at least one post study entry measurement for at least 1 subscale on all 3 questionnaires (EORTC QLQ-C30, EORTC QLQ-MY20 and EQ-5D-5L). Number analyzed are the number of participants with data available for analyses at the given timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline and End of Treatment (Up to 28 cycles, each cycle was of 28 days)","title":"HRQOL Based on EORTC Multiple Myeloma Module 20 (EORTC QLQ-MY20) Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}